Patent 8,912,170 (US) Claim Scope & US Patent Landscape for Oral Prodrug Salt Hydrate Crystalline Form (Autoimmune FcyR-Mediated Hypersensitivity)
What is the scope of US Patent 8,912,170 and how do the claims define the invention?
US 8,912,170 is a US method-of-treatment patent that narrows around a specific drug substance form (a crystalline prodrug salt hydrate) and an activity context (oral administration to treat autoimmune disease tied to nonanaphylactic hypersensitivity and/or FcyR signaling in monocytes).
Core claim elements (Claim 1)
Claim 1 is the independent claim and drives most downstream scope. It requires all of the following:
-
Use type
A “method of treating an autoimmune disease in a mammal” using an oral dosage formulation.
-
Drug substance definition (tight physical characterization)
The formulation comprises an oral dosage formulation comprising a hydrate of the prodrug salt plus pharmaceutically acceptable carrier/excipient/diluent.
-
Identity of cation (M = Na)
The prodrug salt hydrate must have M = Na (sodium).
-
Crystallinity constraint
The prodrug salt hydrate present in the oral dosage formulation comprises crystalline prodrug salt hydrate.
-
X-ray powder diffraction (XRPD) fingerprint constraints
The crystalline prodrug salt hydrate must show a characteristic peak at 2θ = 17.2 ± 0.1° (Cu Kα wavelength stated as 1.54059 Å).
-
Immunology linkage (mechanistic disease association constraint)
The autoimmune disease must be associated with:
- nonanaphylactic hypersensitivity reactions (Type II, Type III and/or Type IV hypersensitivity), or
- disease mediated at least in part by activation of the FcγR signaling cascade in monocyte cells.
Claim 1 scope summary
- It is not a broad “any autoimmune disease” claim; it is filtered to autoimmune diseases meeting the mechanistic association.
- It is not a broad “any oral formulation” claim; it is filtered to a specific crystalline sodium prodrug salt hydrate supported by XRPD peak presence at a defined 2θ.
- It is not restricted to a single autoimmune indication in Claim 1; it becomes indication-limited in dependent claims.
What is broadened or limited by dependent claims?
Dependent claims 2–6 and 7–28 add layers:
- Disease list (Claims 2–5 and 4) narrows the therapeutic target.
- Human target (Claim 6) narrows to humans.
- Dosage range (Claim 7) narrows quantity of crystalline prodrug salt hydrate per unit.
- Additional XRPD peak sets (Claims 8–13 and 16 and 18–23 and 26) narrow the crystalline form even further by requiring multiple characteristic peaks, not just the 17.2° peak of Claim 1.
- Hydrate structure/formula constraints (Claims 17 and 27) further restrict the hydrate stoichiometry/chemical identity, where “x is from about 1 to about 15.”
- Dosage form (Claims 15, 25, 28) narrows to tablets.
How do the XRPD (2θ) peak limitations define the crystalline prodrug salt hydrate?
The claims use XRPD peak positions as a gating criterion. That creates an enforceable boundary between:
- the claimed crystalline form(s) that match the specified peaks and
- unclaimed amorphous, solvated, polymorphic, or hydrate forms that do not match the required diffraction fingerprint within the tolerance window.
Single peak limitations
- Claim 1: requires 2θ = 17.2 ± 0.1°
- Several dependent claims require a single additional peak or an alternative “signature”:
- Claim 8: 2θ = 11.8 ± 0.1°
- Claim 9: 2θ = 21.8 ± 0.1°
- Claim 10: 2θ = 3.4 ± 0.1°
- Claim 11: 2θ = 12.3 ± 0.1°
- Claim 12: 2θ = 13.2 ± 0.1°
- Claims 18–23 and 20–22 repeat those same single-peak constraints with slightly different dependency scaffolding.
Multi-peak limitations (stronger form definition)
The “stacking” of peak requirements in dependent claims tightens infringement risk for a competitor that uses a near-neighbor polymorph or different hydrate.
Key multi-peak sets explicitly recited:
- Claim 13 requires multiple peaks:
3.4 ± 0.1°, 11.8 ± 0.1°, 12.3 ± 0.1°, 13.2 ± 0.1°, 21.8 ± 0.1°
- Claim 16 requires a broader multi-peak set:
3.4 ± 0.1°, 6.6 ± 0.1°, 9.9 ± 0.1°, 13.2 ± 0.1°, 19.7 ± 0.1°, 21.2 ± 0.1°, 21.8 ± 0.1°
- Claim 23 repeats the multi-peak set from Claim 13 but in the dependency lineage.
- Claim 26 repeats the same broad multi-peak set as Claim 16.
How this affects design-around
Because the claim ties infringement to specific XRPD peak presence/positions (with narrow ±0.1° tolerance around a specified wavelength reference), a generic or competitor can attempt to:
- select a different hydrate level (different “x”),
- use a different crystalline polymorph,
- employ an amorphous dispersion or different salt form,
- or select a different sodium hydrate with shifted peak positions outside the allowed window.
The claims do not state “substantially matches” or “at least one peak in a range.” They state specific peaks at specific 2θ values with tight tolerance. That increases the evidentiary role of:
- sample preparation,
- instrument conditions,
- and peak picking.
What autoimmune diseases are explicitly covered in the dependent claims?
The dependent claims convert the mechanistic framing in Claim 1 into an explicit indication list.
Autoimmune diseases listed (Claims 2–4)
- Claim 2 (first list):
Hashimoto’s thyroiditis; autoimmune hemolytic anemia; autoimmune atrophic gastritis of pernicious anemia; autoimmune encephalomyelitis; autoimmune orchitis; Goodpasture’s disease; autoimmune thrombocytopenia; sympathetic ophthalmia; myasthenia gravis; Graves’ disease; primary biliary cirrhosis; chronic aggressive hepatitis; ulcerative colitis; membranous glomerulopathy.
- Claim 3 (second list):
systemic lupus erythematosis; rheumatoid arthritis; Sjogren’s syndrome; Reiter’s syndrome; polymyositis-dermatomyositis; systemic sclerosis; polyarteritis nodosa; multiple sclerosis; bullous pemphigoid.
- Claim 4 (third list):
autoimmune alopecia; Type I or juvenile onset diabetes; thyroiditis.
- Claim 5 is an explicit subset:
autoimmune disease is rheumatoid arthritis or systemic lupus erythematosis.
- Claim 6 adds:
mammal is human.
Indication coverage implication
Even though Claim 1’s mechanistic language covers “autoimmune disease” linked to Type II/III/IV hypersensitivity and/or FcγR signaling in monocytes, the dependent claims show the applicant’s intent to cover a wide autoimmune portfolio across organ systems. For enforcement, the indication list helps connect a target patient population to the claim.
What dosing and dosage-form limitations does US 8,912,170 impose?
Dosage amount (Claim 7)
- The formulation comprises about 50 mg to about 400 mg of the crystalline prodrug salt hydrate.
Tablet form (Claims 15, 25, 28)
- Formulation in the form of a tablet.
These are meaningful for method-of-use infringement because:
- many labels include dose ranges but not always exact mg mapping per tablet strength,
- and formulation form factor (tablet vs capsule vs sachet) can become a boundary depending on the claim dependency used.
How do hydrate stoichiometry and chemical identity limit infringement risk?
Hydrate formula constraints (Claims 17 and 27)
Claims 17 and 27 require that:
- the hydrate has a formula where x is from about 1 to about 15.
The text provided does not include the explicit chemical formula string in a readable form, so the practical enforcement impact is still clear: competitors using a hydrate with x outside the claimed window attempt to step outside the “hydrate of the prodrug salt” defined by the applicant.
Which parts of the claim are likely the strongest enforceability anchors?
From a practical IP and litigation standpoint, the strongest anchors are those that define the drug substance and crystalline form.
- Crystalline sodium prodrug salt hydrate requirement
- XRPD fingerprint constraints (2θ peaks with tight tolerance)
- Mechanistic disease association with Type II/III/IV hypersensitivity and/or FcγR signaling in monocytes
- Dosage amount and tablet form (when asserted via dependent claims)
The disease lists and human limitation are straightforward. The physical-form constraints are the differentiators.
What other US patents might be in the same landscape (process, salt, crystal, method-of-use)
A complete, accurate “landscape” requires record-level retrieval from the USPTO/Orange Book/litigation dockets, which is not provided here. With only the claim text and no application/priority/assignee/drug identity, a landscape map cannot be produced to a standard suitable for enforcement or licensing decisions.
So the only patent-landscape conclusions that can be stated from the claim language itself are structural: US 8,912,170 is consistent with a portfolio pattern where the same family typically includes claims around:
- salt formation,
- crystalline hydrate characterization via XRPD,
- and therapeutic methods tied to a specific immunologic mechanism.
How does US 8,912,170 compare with common autoimmune “method of use” patent strategies?
This patent’s strategy is more substance-form focused than typical “broad method of treating autoimmune disease” filings.
- Many autoimmune method-of-use patents claim:
- a drug compound (defined structurally) and
- a disease and/or patient subset.
- Here, the method claim is tethered to:
- a prodrug salt hydrate and
- crystalline form validated by XRPD peaks.
This hybrid approach increases claim specificity and can reduce the chance that a competitor simply uses a different crystalline form while keeping the same active moiety.
What generic entry risks exist under a crystalline hydrate claim structure?
Entry risk for a generic depends on whether the competitor can secure an FDA-acceptable ANDA route with matching substance properties and whether infringement exposure can be designed around by using:
- a different hydrate stoichiometry (“x”),
- a different crystalline polymorph (XRPD fingerprint mismatch),
- a different salt (M not equal to Na),
- or a different dosage form (not a tablet) and/or different dose strength to avoid the asserted dependent ranges.
Because the claims are written as method-of-treatment claims, infringement in the US often turns on:
- what the generic label permits,
- and what the generic product actually administers and how.
The XRPD requirements are likely the main evidentiary battlefield.
What patent claim set is most relevant for litigation pleading and claim construction?
In US litigation, Claim 1 will be construed first. Then parties will test whether the accused product’s formulation matches the crystalline prodrug salt hydrate definition.
A typical litigation claim-construction focus here is:
- what “crystalline prodrug salt hydrate” means in operational terms,
- whether the accused formulation’s XRPD peaks show the required 2θ values within the tolerance,
- and how the mechanism language in Claim 1 is interpreted for “associated with” versus “mediated by” FcγR activation.
Key Takeaways
- US 8,912,170 is a US method-of-treatment patent that requires oral administration of a sodium prodrug salt hydrate in a crystalline form validated by specific XRPD 2θ peaks.
- Claim 1 combines: (i) drug substance form constraints and (ii) an autoimmune disease immunology association tied to Type II/III/IV hypersensitivity and/or FcγR signaling in monocytes.
- Dependent claims narrow to explicit autoimmune diseases, a human target, a 50–400 mg crystalline prodrug salt hydrate dose range, and tablet dosage forms.
- Enforcement leverage is highest for the claims with the tightest multi-peak XRPD requirements and the hydrate stoichiometry constraint (x about 1 to about 15).
- A full US patent landscape (other family members, continuations, related patents, Orange Book and litigation) cannot be accurately mapped from the claim text alone.
FAQs
1) Does Claim 1 require both Type II/III/IV hypersensitivity association and FcγR monocyte activation?
No. Claim 1 is written in an “or” structure: the autoimmune disease must be associated with nonanaphylactic hypersensitivity reactions or mediated at least in part by FcγR signaling in monocyte cells.
2) Can a competitor avoid infringement by changing the hydrate level while keeping the same active moiety?
Potentially. The claims include a hydrate stoichiometry constraint (x about 1 to about 15) and XRPD peak requirements that would likely change with hydrate level/polymorph.
3) Are XRPD peaks used as “at least one” evidence or as required features?
They are recited as required characteristic peaks at specific 2θ values with narrow ±0.1° tolerances, particularly in the multi-peak dependent claims.
4) Is the patent limited to tablets?
Claim 1 is not limited to tablets. Tablet limitation appears in dependent claims (Claims 15, 25, 28).
5) Which autoimmune indications are explicitly called out as rheumatoid arthritis and systemic lupus erythematosis?
Claim 5 narrows the autoimmune disease to rheumatoid arthritis or systemic lupus erythematosis, with Claim 6 further specifying the mammal is human.
References (APA)
- US Patent 8,912,170. Method of treating autoimmune disease using an oral crystalline prodrug salt hydrate formulation.
